Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.